In agreement with our results, Akbari et al. demonstrated that saroglitazar ameliorates hepatic steatosis, reduces serum ALT and AST levels, and down-regulates the level of pro-inflammatory cytokines in the HFD-induced NASH group (24). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.